Literature DB >> 20127276

sHLA-I Contamination, a novel mechanism to explain ex vivo/in vitro modulation of IL-10 synthesis and release in CD8(+) T lymphocytes and in neutrophils following intravenous immunoglobulin infusion.

Massimo Ghio1, Paola Contini, Maurizio Setti, Gianluca Ubezio, Clemente Mazzei, Gino Tripodi.   

Abstract

BACKGROUND: Numerous mechanisms have been proposed to explain the beneficial action of intravenous immune globulin (IVIG) in autoimmune and systemic inflammatory disorders; among others, they could decrease pro-inflammatory cytokine levels and also induce anti-inflammatory cytokines.
MATERIALS AND METHODS: Ex vivo analysis of cells from ten IVIG recipients showed significant increase of IL-10 mRNA and intra-cellular IL-10 molecules in both leukotypes.
RESULTS: In vitro comparable results were obtained incubating CD8(+) T lymphocytes and neutrophils from healthy donors with IVIG. sHLA-I and/or sFasL immunodepletion abolished IL-10 modulation. Co-culture with contaminant-free IgM or MabThera did not exert any mRNA modulation. Finally, IgM or MabThera plus purified sHLA-I molecules enhanced IL-10-mRNA in both leukotypes to levels comparable to those obtained with IVIG incubation.
CONCLUSION: As IVIG infusion involves administration of soluble contaminants, these data consent to speculate that IVIG might modulate IL-10 via the immunomodulatory activities of sHLA-I contaminant molecules inducing transcriptional and post-transcriptional modulation of IL-10 in CD8(+) T lymphocytes and neutrophils.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127276     DOI: 10.1007/s10875-009-9364-y

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  45 in total

Review 1.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

Authors:  M D Kazatchkine; S V Kaveri
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

Review 2.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

3.  Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction.

Authors:  Grazia Maria Spaggiari; Paola Contini; Alessandra Dondero; Roberta Carosio; Francesco Puppo; Francesco Indiveri; Maria Raffaella Zocchi; Alessandro Poggi
Journal:  Blood       Date:  2002-07-18       Impact factor: 22.113

Review 4.  Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.

Authors:  Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Michel D Kazatchkine; Srini V Kaveri
Journal:  Nat Clin Pract Rheumatol       Date:  2007-05

5.  Shortage of human intravenous immunoglobulin--reasons and possible solutions.

Authors:  Jagadeesh Bayry; Michel D Kazatchkine; Srini V Kaveri
Journal:  Nat Clin Pract Neurol       Date:  2007-03

6.  The antiinflammatory IgG.

Authors:  Srini V Kaveri; Sébastien Lacroix-Desmazes; Jagadeesh Bayry
Journal:  N Engl J Med       Date:  2008-07-17       Impact factor: 91.245

7.  Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis.

Authors:  Athanasia Mouzaki; Maria Theodoropoulou; Ioannis Gianakopoulos; Vassiliki Vlaha; Maria-Christina Kyrtsonis; Alice Maniatis
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

Review 8.  Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside.

Authors:  G Zandman-Goddard; M Blank; Y Shoenfeld
Journal:  Lupus       Date:  2009-09       Impact factor: 2.911

9.  Immunomodulatory effects of blood transfusions: the synergic role of soluble HLA Class I free heavy-chain molecules detectable in blood components.

Authors:  Massimo Ghio; Paola Contini; Gianluca Ubezio; Clemente Mazzei; Franco Puppo; Franco Indiveri
Journal:  Transfusion       Date:  2008-05-06       Impact factor: 3.157

10.  Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway.

Authors:  N K Prasad; G Papoff; A Zeuner; E Bonnin; M D Kazatchkine; G Ruberti; S V Kaveri
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

View more
  3 in total

Review 1.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

2.  Bio-modulators in platelet-rich plasma: a comparison of the amounts in products from healthy donors and patients produced with three different techniques.

Authors:  Gianluca Ubezio; Massimo Ghio; Paola Contini; Roberta Bertorello; Gennaro Marino; Andrea Tomasini; Gino Tripodi
Journal:  Blood Transfus       Date:  2013-01-23       Impact factor: 3.443

3.  Intravenous immunoglobulin replacement therapy in the treatment of patients with common variable immunodeficiency disease: an open-label prospective study.

Authors:  Karolina Kasztalska; Maciej Ciebiada; Barbara Cebula-Obrzut; Paweł Górski
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.